Fitxers

1-s2.0-S1556086425028540-main.pdf (657.91 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2025-10-22

Llicència de publicació

cc-by-nc-nd (c) Di Frisco, Madeleine et al., 2025
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/228115

Brief Report: Emphysema as a Prognostic Factor in Patients With Advanced NSCLC With COPD Receiving Immune Checkpoint Inhibitors

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1016/j.jtho.2025.10.007

Resum

Introduction: Chronic obstructive pulmonary disease (COPD) and emphysema are independent risk factors for lung cancer development and have been independently associated with longer overall survival (OS) in patients with NSCLC treated with immune checkpoint inhibitors (ICIs). However, their combined impact on prognosis remains unclear. This study evaluates emphysema as a prognostic factor in patients with COPD with advanced NSCLC (aNSCLC) undergoing immunotherapy. Methods: This study included patients with aNSCLC with COPD (defined by spirometry) treated with single-agent ICI as first-or second-line treatment, from 2013 to 2024. Patients were classified based on visually detected emphysema on chest computed tomography. Results: The study included 111 patients with COPD, of whom 77 had coexisting emphysema. Patients with COPD and emphysema had significantly longer OS compared with those without emphysema (17.3 versus 8.5 mo, p = 0.008), with a nonsignificant trend toward improved progression-free survival (3.3 versus 2.4 mo, p = 0.641). Emphysema remained an independent factor of better OS in multivariate analysis (hazard ratio: 0.49; 95% confidence interval: 0.30-0.81). Adverse event rates were similar regardless of emphysema status (p = 0.455). Conclusions: This study suggests that visually detected emphysema on chest computed tomography could be a potential prognostic marker in patients with aNSCLC with COPD receiving ICIs. Further studies are guaranteed to confirm these findings.

Matèries

Malalties de l'aparell respiratori, Càncer de pulmó

Matèries (anglès)

Respiratory diseases, Lung cancer

Citació

Col·leccions

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

DI FRISCO, Madeleine, et al. Brief Report: Emphysema as a Prognostic Factor in Patients With Advanced NSCLC With COPD Receiving Immune Checkpoint Inhibitors. Journal of Thoracic Oncology. 2025. Vol. 21, num. 2, pags. 328-333. ISSN 1556-0864. [consulted: 24 of May of 2026]. Available at: https://hdl.handle.net/2445/228115

Exportar metadades

JSON - METS

Compartir registre